Jim Cramer turns bullish on health care stock after years of doubt
Key takeaways
- The Cambridge, Massachusetts, company had become synonymous with the pandemic trade, and Cramer's enthusiasm faded as demand for Covid-era vaccines dried up.
- That changed on his "Mad Money" show on July 1, when Cramer declared Moderna finally investable again.
- The stock still trades well below its pandemic-era closing high of $484.47, reached in August 2021, according to Macrotrends.
Jim Cramer turns bullish on health care stock after years of doubt Damilola Esebame Fri, July 3, 2026 at 11:03 PM GMT+7 5 min read MRNA ^GSPC For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism bordering on avoidance.
The Cambridge, Massachusetts, company had become synonymous with the pandemic trade, and Cramer's enthusiasm faded as demand for Covid-era vaccines dried up.
That changed on his "Mad Money" show on July 1, when Cramer declared Moderna finally investable again. He cited a pipeline overhaul that stretches into cancer treatment, rare diseases, and a groundbreaking new flu shot. Shares have surged roughly 150% in 2026, making Moderna one of the best-performing names in the S&P 500, CNBC reported.